DOCSLIB.ORG

Annual Report of Proxy Voting Record Date

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report of Proxy Voting Record Date ANNUAL REPORT OF PROXY VOTING RECORD DATE OF REPORTING PERIOD: JULY 1, 2018 - JUNE 30, 2019 FUND: VANGUARD FTSE 100 UCITS ETF --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: 3i Group Plc TICKER: III CUSIP: G88473148 MEETING DATE: 6/27/2019 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #3: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #4: RE-ELECT JONATHAN ASQUITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: RE-ELECT CAROLINE BANSZKY AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: RE-ELECT SIMON BORROWS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT STEPHEN DAINTITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT PETER GROSCH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: RE-ELECT DAVID HUTCHISON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: ELECT COLINE MCCONVILLE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #11: RE-ELECT SIMON THOMPSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #12: RE-ELECT JULIA WILSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #13: REAPPOINT ERNST & YOUNG LLP AS AUDITORS ISSUER YES FOR FOR PROPOSAL #14: AUTHORISE BOARD ACTING THROUGH THE ISSUER YES FOR FOR AUDIT AND COMPLIANCE COMMITTEE TO FIX REMUNERATION OF AUDITORS PROPOSAL #15: AUTHORISE EU POLITICAL DONATIONS AND ISSUER YES FOR FOR EXPENDITURE PROPOSAL #16: AUTHORISE ISSUE OF EQUITY ISSUER YES FOR FOR PROPOSAL #17: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS PROPOSAL #18: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS IN CONNECTION WITH AN ACQUISITION OR OTHER CAPITAL INVESTMENT PROPOSAL #19: AUTHORISE MARKET PURCHASE OF ORDINARY ISSUER YES FOR FOR SHARES PROPOSAL #20: AUTHORISE THE COMPANY TO CALL GENERAL ISSUER YES FOR FOR MEETING WITH TWO WEEKS' NOTICE --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: Admiral Group Plc TICKER: ADM CUSIP: G0110T106 MEETING DATE: 4/25/2019 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #3: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #4: ELECT MICHAEL BRIERLEY AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: ELECT KAREN GREEN AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: RE-ELECT ANNETTE COURT AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT DAVID STEVENS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT GERAINT JONES AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: RE-ELECT JEAN PARK AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: RE-ELECT MANNING ROUNTREE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #11: RE-ELECT OWEN CLARKE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #12: RE-ELECT JUSTINE ROBERTS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #13: RE-ELECT ANDREW CROSSLEY AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #14: REAPPOINT DELOITTE LLP AS AUDITORS ISSUER YES FOR FOR PROPOSAL #15: AUTHORISE THE AUDIT COMMITTEE TO FIX ISSUER YES FOR FOR REMUNERATION OF AUDITORS PROPOSAL #16: AUTHORISE EU POLITICAL DONATIONS AND ISSUER YES FOR FOR EXPENDITURE PROPOSAL #17: AUTHORISE ISSUE OF EQUITY ISSUER YES FOR FOR PROPOSAL #18: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS PROPOSAL #19: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS IN CONNECTION WITH AN ACQUISITION OR OTHER CAPITAL INVESTMENT PROPOSAL #20: AUTHORISE MARKET PURCHASE OF ORDINARY ISSUER YES FOR FOR SHARES PROPOSAL #21: AUTHORISE THE COMPANY TO CALL GENERAL ISSUER YES FOR FOR MEETING WITH TWO WEEKS' NOTICE --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: Anglo American Plc TICKER: AAL CUSIP: G03764134 MEETING DATE: 4/30/2019 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #3: ELECT MARCELO BASTOS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #4: RE-ELECT IAN ASHBY AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: RE-ELECT STUART CHAMBERS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: RE-ELECT MARK CUTIFANI AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT NOLITHA FAKUDE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT BYRON GROTE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: RE-ELECT TONY O'NEILL AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: RE-ELECT STEPHEN PEARCE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #11: RE-ELECT MPHU RAMATLAPENG AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #12: RE-ELECT JIM RUTHERFORD AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #13: RE-ELECT ANNE STEVENS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #14: REAPPOINT DELOITTE LLP AS AUDITORS ISSUER YES FOR FOR PROPOSAL #15: AUTHORISE BOARD TO FIX REMUNERATION OF ISSUER YES FOR FOR AUDITORS PROPOSAL #16: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #17: AUTHORISE ISSUE OF EQUITY WITH PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS PROPOSAL #18: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS PROPOSAL #19: AUTHORISE MARKET PURCHASE OF ORDINARY ISSUER YES FOR FOR SHARES PROPOSAL #20: AUTHORISE THE COMPANY TO CALL GENERAL ISSUER YES FOR FOR MEETING WITH TWO WEEKS' NOTICE --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: Antofagasta Plc TICKER: ANTO CUSIP: G0398N128 MEETING DATE: 5/22/2019 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #3: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #4: RE-ELECT JEAN-PAUL LUKSIC AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: RE-ELECT OLLIE OLIVEIRA AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: RE-ELECT GONZALO MENENDEZ AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT RAMON JARA AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT JUAN CLARO AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: RE-ELECT TIM BAKER AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: RE-ELECT ANDRONICO LUKSIC AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #11: RE-ELECT VIVIANNE BLANLOT AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #12: RE-ELECT JORGE BANDE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #13: RE-ELECT FRANCISCA CASTRO AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #14: ELECT MICHAEL ANGLIN AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #15: REAPPOINT PRICEWATERHOUSECOOPERS LLP AS ISSUER YES FOR FOR AUDITORS PROPOSAL #16: AUTHORISE THE AUDIT AND RISK COMMITTEE ISSUER YES FOR FOR TO FIX REMUNERATION OF AUDITORS PROPOSAL #17: AUTHORISE ISSUE OF EQUITY ISSUER YES FOR FOR PROPOSAL #18: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS PROPOSAL #19: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS IN CONNECTION WITH AN ACQUISITION OR OTHER CAPITAL INVESTMENT PROPOSAL #20: AUTHORISE MARKET PURCHASE OF ORDINARY ISSUER YES FOR FOR SHARES PROPOSAL #21: AUTHORISE THE COMPANY TO CALL GENERAL ISSUER YES FOR FOR MEETING WITH TWO WEEKS' NOTICE --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: Ashtead Group plc TICKER: AHT CUSIP: G05320109 MEETING DATE: 9/11/2018 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #3: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #4: RE-ELECT GEOFF DRABBLE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: RE-ELECT BRENDAN HORGAN AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: ELECT MICHAEL PRATT AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT IAN SUTCLIFFE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT LUCINDA RICHES AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: RE-ELECT TANYA FRATTO AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: ELECT PAUL WALKER AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #11: REAPPOINT DELOITTE LLP AS AUDITORS ISSUER YES FOR FOR PROPOSAL #12: AUTHORISE BOARD TO FIX REMUNERATION OF ISSUER YES FOR FOR AUDITORS PROPOSAL #13: AUTHORISE ISSUE OF EQUITY WITH PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS PROPOSAL #14: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS PROPOSAL #15: AUTHORISE ISSUE OF EQUITY WITHOUT PRE- ISSUER YES FOR FOR EMPTIVE RIGHTS IN CONNECTION WITH AN ACQUISITION OR OTHER CAPITAL INVESTMENT PROPOSAL #16: AUTHORISE MARKET PURCHASE OF ORDINARY ISSUER YES FOR FOR SHARES PROPOSAL #17: AUTHORISE THE COMPANY TO CALL GENERAL ISSUER YES FOR FOR MEETING WITH TWO WEEKS' NOTICE --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: Associated British Foods Plc TICKER: ABF CUSIP: G05600138 MEETING DATE: 12/7/2018 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS
Load more

Recommended publications
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GENOCEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 372427 10 4 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 30, 2015 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    [Show full text]
  • Governance and Remuneration 2014
    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
    [Show full text]
  • Britvic Annual Report 2008
    Britvic plc Britvic plc Britvic House Broomfield Road 2008 Annual Report Britvic plc Chelmsford Essex CM1 1TU Annual Report 2008 Telephone 01245 261871 Fax 01245 267147 www.britvic.com Electronic communications Shareholders can elect to receive shareholder documents electronically by registering with Shareview at www.shareview.co.uk Who We Are This will save on printing and distribution costs, creating environmental benefits. When you register, you will be sent an email notification to say when shareholder documents are available on our website and you will be provided with a link to that information. Britvic is one of the two leading branded soft drinks When registering, you will need your shareholder reference number which can be found on your share certificate or proxy form. businesses in the UK and the Republic of Ireland. Many Please contact Equiniti if you require any assistance or further information. Contacts of our brands are either first or second in their respective The Company Secretary is John Price and the registered office is Britvic House, Broomfield Road, Chelmsford CM1 1TU, categories. We have a strong track record of innovation telephone 01245 504482, fax 01245 504435, website www.britvic.com The Company’s Registrar is Equiniti, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, telephone 0871 384 2520* in products, packaging and marketing activity. In 2007 (UK callers) +44 121 415 7047 (non-UK callers). we expanded into Ireland with a significant acquisition * For those with hearing difficulties, a textphone is available on 0871 384 2255 for UK callers with compatible equipment. Further copies of this report are available from the Company’s registered office (address as above) and may be accessed through and we have a long-standing bottling agreement the Company’s website, www.britvic.com with PepsiCo for key brands such as Pepsi, 7UP and Gatorade in UK and Ireland.
    [Show full text]
  • Vote Summary Report Reporting Period: 07/01/2017 to 06/30/2018 Location(S): All Locations
    Vote Summary Report Reporting Period: 07/01/2017 to 06/30/2018 Location(s): All Locations BGP Holdings Plc Meeting Date: 07/03/2017 Country: Malta Primary Security ID: Record Date: 05/25/2017 Meeting Type: Special Ticker: N/A Proposal Vote Number Proposal Text Proponent Mgmt Rec Instruction 1 Approve Reduction of Share Premium Account Mgmt For For 2 Approve Distribution of EUR 5 Million to Mgmt For For Directors 3 Approve Distribution of EUR 1.5 Million to Mgmt For For Directors Red Rock Resorts, Inc. Meeting Date: 07/06/2017 Country: USA Primary Security ID: 75700L108 Record Date: 05/08/2017 Meeting Type: Annual Ticker: RRR Proposal Vote Number Proposal Text Proponent Mgmt Rec Instruction 1.1 Elect Director Frank J. Fertitta, III Mgmt For For 1.2 Elect Director Lorenzo J. Fertitta Mgmt For For 1.3 Elect Director Robert A. Cashell, Jr. Mgmt For For 1.4 Elect Director Robert E. Lewis Mgmt For For 1.5 Elect Director James E. Nave Mgmt For For 2 Advisory Vote to Ratify Named Executive Mgmt For For Officers' Compensation 3 Advisory Vote on Say on Pay Frequency Mgmt One Year One Year 4 Ratify Ernst & Young LLP as Auditors Mgmt For For LondonMetric Property Plc Meeting Date: 07/11/2017 Country: United Kingdom Primary Security ID: G5689W109 Record Date: 07/07/2017 Meeting Type: Annual Ticker: LMP Vote Summary Report Reporting Period: 07/01/2017 to 06/30/2018 Location(s): All Locations LondonMetric Property Plc Proposal Vote Number Proposal Text Proponent Mgmt Rec Instruction 1 Accept Financial Statements and Statutory Mgmt For For Reports 2
    [Show full text]
  • What Makes a Great Chief Executive? What Makes a Great Chief Executive? Material Consists of 80% Recycled Certification
    Material consists of 80% recycled post-consumer fibre; 10% TCF (totally chlorine free); 10% ECF (elemental chlorine free). FSC certification. NAPM recycled certification. Paper mill accredited with ISO 9001 and ISO 14001 status. All responsibilities to the local environment and manufacturing processes are strictly monitored. The Whitehead Mann Leadership Debate Leadership Mann Whitehead The What makes a great Chief Executive? Chief great a makes What THE WHITEHEAD MANN LEADERSHIP DEBATE LEADERSHIP MANN WHITEHEAD THE What makes a great Chief Executive? Chief agreat What makes Contact Carol Leonard All rights reserved. No part of this publication Whitehead Mann is one of the world’s best-known leadership consultancies may be reproduced, stored in a retrieval system, working with clients to create value through people. As an independent, Whitehead Mann or transmitted in any form or by any means, international partnership, we work as a single team to deliver deep sector Ryder Court electronic, mechanical, photocopying, recording and functional expertise. We are authorities in the areas of leadership; CEO 14 Ryder Street or otherwise, without the express permission concerns; CEO characteristics and career issues at Board and CEO level. London SW1Y 6QB of the copyright owner. Our long track record is built on our contacts, judgement, the quality of our t +44 (0) 207 024 9000 © The Whitehead Mann Partnership LLP board placements and our ability to identify the CEOs of tomorrow. Over 90 f +44 (0) 207 024 9001 of Europe’s top 200 companies and most of the FTSE 100 companies and e [email protected] Fortune 500 organisations have retained Whitehead Mann.
    [Show full text]
  • Congress Guide
    INTERNATIONAL CONGRESS 2015 AMSTERDAM netherlands, 26–30 september CONGRESS GUIDE ERSCONGRESS.ORG ERS AMSTERDAM 2015 WelprogrammeCome TO amS outlineterDam ■ WELCOME FROM THE ERS PRESIDENT I am honoured to be hosting the 25th International Congress of the European Respiratory Society in my home city of Amsterdam. Amsterdam is famous for its international trade and it is fitting that the ERS Congress is held in a city that has reaped the benefits from an international outlook. It is imperative that we, as respiratory professionals, mirror this approach and work together as an international network to achieve our goal of promoting lung health and combating lung diseases. The scientific and educational programme promises to deliver a wealth of new material from all sections of respiratory health and disease. The Chairs of the Scientific and Education Councils, together with all the ERS officers, work on the programme throughout the year to ensure it delivers the very best results from the latest Professor Elisabeth Bel research, meeting the needs of respiratory professionals ERS PRESIDENT in all disciplines. This year we have taken the landmark decision to provide the congress scientific and educational programme in a digital format only. With the growth in digital platforms over the last ten years, there is no better time to provide our delegates with all the materials and tools needed in a digital format. Instead of a printed copy, the programme will be available on the Congress website where users can easily browse all the sessions, build their own personal itinerary, and download and print abstracts of interest. All these features will also be available on the Congress App, which is free to download and will be available from August.
    [Show full text]
  • Engagement, Screening and Voting Report 2018
    Engagement, Screening and Voting Report 2018 Carlota Garcia-Manas and Sheila Stefani Responsible Investment Team INTRODUCTION Contents Introduction .............................................................................................................................. 3 Engagement ............................................................................................................................. 5 Screening ............................................................................................................................... 12 Voting: Overview ..................................................................................................................... 14 Voting: Management Resolutions (UK) .................................................................................... 16 Overview ............................................................................................................................ 16 Remuneration (UK) ............................................................................................................. 17 Directors (UK) ..................................................................................................................... 18 Voting: Management Resolutions (Global) ............................................................................... 20 Overview ............................................................................................................................ 20 Remuneration (Global) .......................................................................................................
    [Show full text]
  • X-Ray Fluorescence Analysis Method Röntgenfluoreszenz-Analyseverfahren Procédé D’Analyse Par Rayons X Fluorescents
    (19) & (11) EP 2 084 519 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 23/223 (2006.01) G01T 1/36 (2006.01) 01.08.2012 Bulletin 2012/31 C12Q 1/00 (2006.01) (21) Application number: 07874491.9 (86) International application number: PCT/US2007/021888 (22) Date of filing: 10.10.2007 (87) International publication number: WO 2008/127291 (23.10.2008 Gazette 2008/43) (54) X-RAY FLUORESCENCE ANALYSIS METHOD RÖNTGENFLUORESZENZ-ANALYSEVERFAHREN PROCÉDÉ D’ANALYSE PAR RAYONS X FLUORESCENTS (84) Designated Contracting States: • BURRELL, Anthony, K. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: Albrecht, Thomas Kraus & Weisert (30) Priority: 10.10.2006 US 850594 P Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15 (43) Date of publication of application: 80539 München (DE) 05.08.2009 Bulletin 2009/32 (56) References cited: (60) Divisional application: JP-A- 2001 289 802 US-A1- 2003 027 129 12164870.3 US-A1- 2003 027 129 US-A1- 2004 004 183 US-A1- 2004 017 884 US-A1- 2004 017 884 (73) Proprietors: US-A1- 2004 093 526 US-A1- 2004 235 059 • Los Alamos National Security, LLC US-A1- 2004 235 059 US-A1- 2005 011 818 Los Alamos, NM 87545 (US) US-A1- 2005 011 818 US-B1- 6 329 209 • Caldera Pharmaceuticals, INC. US-B2- 6 719 147 Los Alamos, NM 87544 (US) • GOLDIN E M ET AL: "Quantitation of antibody (72) Inventors: binding to cell surface antigens by X-ray • BIRNBAUM, Eva, R.
    [Show full text]
  • Press Release
    PRESS RELEASE Issued: Tuesday 20 September 2016, London UK – LSE Announcement Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline GSK today announces that Emma Walmsley, currently Chief Executive Officer (CEO) of GSK’s Consumer Healthcare division, is appointed GSK CEO Designate and will succeed Andrew Witty as GSK CEO, when he retires on 31March 2017. Emma will join the GSK Board of Directors from 1 January 2017. Emma is currently CEO of GSK Consumer Healthcare, one of the world’s largest consumer health companies, established in 2015 following completion of GSK’s three-part transaction with Novartis. Prior to this, Emma was President of GSK Consumer Healthcare and has been a member of GSK’s Corporate Executive Team since 2011. Emma joined GSK in 2010 from L’Oreal where, over the course of her 17-year career, she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China. Philip Hampton, GSK Chairman, said: “I am very pleased to announce Emma’s appointment, after what has been a very thorough and rigorous global selection process carried out by the GSK Board of Directors. Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare. Under Andrew’s leadership, GSK has successfully developed into a company with market-leading positions in pharmaceuticals, vaccines and consumer healthcare. These provide excellent platforms for sustainable, long-term growth, and we are confident Emma will successfully build on these strengths.” Emma Walmsley said: “I am delighted and honoured to be appointed GSK’s next CEO.
    [Show full text]
  • View Annual Report
    Annual Report 2016 making life’s everyday moments more enjoyable Contents Strategic report 2 Chairman’s introduction 4 Britvic at a glance 6 Our brands 8 Our business model 10 Trends 11 Our geographies 12 Our strategy 14 Key performance indicators 16 Chief Executive Officer’s review 19 Chief Financial Officer’s review 24 Sustainable business review 28 Our risks 32 Viability statement Governance 34 Corporate governance report 36 Board of directors 47 Nomination committee 50 Audit Committee 58 Remuneration Committee 59 Directors’ remuneration report 61 At a glance 67 Annual Report on Remuneration 76 Directors’ Remuneration Policy 85 Directors’ report 88 Statement of directors’ responsibilities Financial statements 90 Independent Auditor’s Report to the members of Britvic plc 96 Consolidated income statement 97 Consolidated statement of comprehensive income/(expense) 98 Consolidated balance sheet 99 Consolidated statement of cash flows 100 Consolidated statement of changes in equity 101 Notes to the consolidated financial statements 148 Company balance sheet 149 Company cash flow statement 150 Company statement of changes in equity 151 Notes to the company financial statements Other information 160 Shareholder information 162 Glossary 163 Non-GAAP reconciliations Cautionary note regarding forward-looking statements This announcement includes statements that are forward-looking in nature. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the group to be materially different from any future results, Britvic takes care of the environment by choosing pureprint® environmental print performance or achievements expressed or implied by such forward-looking technology. All the electricity used in the production of this report was generated from renewable sources and vegetable oil based inks were used throughout.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]
  • Annual Report 2015
    Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
    [Show full text]